Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > More dilution

<< Previous

Bullboard Posts

Next >>

Comment by Forestviewon Jan 06, 2021 12:49pm

129 Views

Post# 32233840

RE:More dilution

Interesting take. So you want them to dilute solely for the reason that you can up your stake? They do that, and we will be potentially hit with another hurdle that will artificially keep the price of the share from going beyond. I just don't understand what strategic reason they'd have to do that at this point.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments